Document is current
Any future updates will be listed below
-
Authors
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
Kim, Dong-Wook https://orcid.org/0000-0003-3967-4267
Cortes, Jorge E. https://orcid.org/0000-0002-8636-1071
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Mauro, Michael J. https://orcid.org/0000-0002-2251-4032
Hughes, Timothy P. https://orcid.org/0000-0002-0910-3730
Breccia, Massimo https://orcid.org/0000-0003-1163-6162
Talpaz, Moshe https://orcid.org/0000-0003-3361-3981
Minami, Hironobu
Goh, Yeow Tee https://orcid.org/0000-0002-7069-0997
DeAngelo, Daniel J. https://orcid.org/0000-0001-7865-2306
Lang, Fabian https://orcid.org/0000-0003-2890-029X
Ottmann, Oliver
Heinrich, Michael C. https://orcid.org/0000-0003-3790-0478
Gomez Garcia de Soria, Valle
le Coutre, Philipp
Sanchez-Olle, Gessami
Cao, Meng https://orcid.org/0000-0002-3338-304X
Pognan, Nathalie
Kapoor, Shruti
Hoch, Matthias
Rea, Delphine
-
Funding
Funding for this research was provided by:
Novartis
- License Information
-
More Information
Article History
Received: 21 February 2025
Revised: 10 March 2025
Accepted: 19 March 2025
First Online: 9 April 2025
Competing interests
: AH: Bristol Myers Squibb, TERNS, Enliven, and Pfizer: institutional research support; Novartis and Incyte: institutional research support, personal fees. D-WK: Novartis, Bristol Myers Squibb, Pfizer, II-Yand, and Takeda: grants. JEC: Novartis, Pfizer, and Bristol Myers Squibb: grants, consulting fees. KS: Novartis: research funding, honoraria. MJM: Bristol Myers Squibb, Takeda, and Pfizer: personal fees. TPH: Novartis, Bristol Myers Squibb, and Enliven: consultancy, research funding. MB: Bristol Myers Squibb, Celgene, Pfizer, Incyte, and Novartis: consultancy and honoraria; AbbVie: consultancy. MT: Imago: consultancy; Novartis and Takeda: research funding; Constellation Pharmaceuticals and Bristol Myers Squibb: membership on board of directors or advisory committees. HM: Bayer, Bristol Myers Squibb Japan, Celgene, Chugai Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Kyowa Hakko Kirin, Lilly Japan, Novartis, Ono Pharmaceutical, Otsuka, Pfizer, Taiho Pharmaceutical, Takeda, MSD, and AbbVie: honoraria; Ono Pharmaceutical: consulting; Astellas Pharma, Chugai Pharma, Dainippon Sumitomo Pharma, Eisai, Kyowa Hakko Kirin, Lilly Japan, Ono Pharmaceutical, Taiho Pharmaceutical, Nippon Shinyaku, MSD, Boehringer Ingelheim, Daiichi Sankyo, Takeda, Nihonkayaku, Shionogi, Sanofi, Bayer Schering Pharma, Mitsubishi Tanabe Pharma, and Teijin Pharma: research funding. YTG: Pfizer, Johnson & Johnson, Amgen, MSD Pharma, Novartis, EUSA Pharma, Roche, Bristol Myers Squibb, and AbbVie: honoraria. DJD: AbbVie, Novartis, Blueprint, and GlycoMimetics: grants; AbbVie, Novartis, Blueprint, and GlycoMimetics: research funding; Amgen, Autolus, Blueprint, Forty-Seven, GlycoMimetics, Gilead, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda; consulting. AbbVie, Amgen, Autolus, Blueprint, Daiichi Sankyo, Forty-Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda: personal fees. FL: Bristol Myers Squibb, Incyte, and Celgene: consultancy, honoraria; Novartis: consultancy, honoraria, and research funding. OO: Incyte and Amgen: honoraria. MCH: Jonathan David Foundation (VA Merit Review grant [I01BX005358] and NCI R21 grant [R21CA263400]): partial salary support; Novartis, Deciphera, New Bay Pharmaceuticals, Cogent, IDRX, Theseus Pharmaceuticals: consulting; von Pfeffel Pharmaceuticals: SAB; Novartis: patents/royalties/other intellectual property licensed to Novartis (institutional license; treatment of GIST). VGGdS: Novartis, Pfizer, Bristol Myers Squibb, and Incyte: grants, nonfinancial support, and honoraria. PlC: Pfizer, Novartis, and Incyte: honoraria. GSO, MC, NP, SK, and MH are employees of Novartis. DR: Novartis, Pfizer, and Incyte: personal fees.
